Back to Search

A Phase 1/1b Study of SRF388 in Patients With Advanced Solid Tumors

  • Protocol Number: 202004075
  • Principal Investigator: Morgensztern, Daniel
  • Cancer Types: Early Phase, Lung

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.

Protocol Interventions

SRF388, Pembrolizumab